Recommendation of the President – Trandate (labetalol)
On 6 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 139/2024 on the appropriateness of issuing approvals for the reimbursement of the medicinal product Trandate (labetalol) for the indication: hypertension in pregnant women